How much funding has ArriVent raised?

ArriVent has raised $305.0M in total funding, most recently a Series B round.

Who are ArriVent's investors?

ArriVent's investors include General Catalyst, Sofinnova Investments, Hillhouse Capital, Lilly Asia Ventures, OrbiMed, Octagon Capital Advisors.

Where is ArriVent headquartered?

ArriVent is headquartered in Newtown Square, Pennsylvania, United States.

What industry is ArriVent in?

ArriVent operates in Biotech, Healthcare, Life Sciences, Oncology.

ArriVent

formerly ArriVent BioPharmaIPO

Home - ArriVent BioPharma

Public · Newtown Square, United States · Founded 2021 · $305.0M raised

Headquarters: Newtown Square, Pennsylvania
Employees: 11–50
Founded: 2021
Business Model: B2B
Website: arrivent.com

Total Funding: $305.0M
Last Round: $155.0M Series BMar 2023
Rounds: 2
Type: Public

About

ArriVent BioPharma was founded in 2021 to identify, develop, and commercialize differentiated medicines from around the world — particularly innovative therapies initially developed in China, Europe, South Korea, and Japan that might not otherwise reach global patients. The company applies deep oncology expertise and regulatory knowledge to in-license clinical-stage candidates with strong biological rationale and a clear path to approval.

Summary

ArriVent is a Biotech company based in Newtown Square, United States, founded in 2021. It has raised $305.0M in total across 2 rounds, most recently a $155.0M Series B round in Mar 2023. Investors include General Catalyst, Sofinnova Investments and Hillhouse Capital.